VIP
A vasoactive intestinal peptide associated with neuroimmune and inflammatory signaling discussions.
Also referenced as: Vasoactive Intestinal Peptide
This compound has a genuine development or study trail, but it is not an approved routine drug.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
Vasoactive Intestinal Peptide
No FDA label signal · 54 trials · 1000 PubMed results
VIP has human trials registered, but none have reported controlled results yet. Most current claims about what it does in people rest on preclinical (lab or animal) work, not published human data.
VIP has 5 name-matched clinical trials (highest phase: Phase 1) and 1000 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet. Note: 8 retracted publications in the literature.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What VIP is
VIP stands for vasoactive intestinal peptide, a signaling peptide that shows up in immune, inflammatory, and neuroregulatory discussions.
Why it matters
It broadens the immune category beyond simple host-defense framing and reflects the fact that some peptide interest is really about signaling networks rather than bodybuilding or cosmetic use.
Regulatory context
VIP is not an FDA-approved general wellness peptide in the United States. It is best treated as an investigational or research-context entry.
Practical reading note
The more complex the signaling story around a peptide, the more important it is to avoid collapsing it into simple consumer promises.